Remedy is price-led marketing over thin public paper: aggressive advertised rates, sparse documentation of pharmacy, workflow, and fee stack. The documentation gap is itself the current finding — not a verdict, but the reason this file is short on facts and long on interrogation. Queue position 8.
The model
Remedy Meds is a newer compounded-telehealth entrant that shows up in ad placements with aggressive introductory pricing and comparatively thin public documentation — no deep press coverage, limited third-party reporting. That is precisely the profile where a verification-first ledger earns its keep: the gap between an advertised first-month price and the true recurring cost is historically widest among lesser-documented entrants. Until our pass completes, every Remedy figure should be read as an unverified advertised price.
The ledger file
| Medications offered | Pending verification |
|---|---|
| Formats | Pending verification |
| Advertised starting price | Pending verification |
| True recurring price (maintenance dose) | Pending verification |
| Membership fee | Pending verification |
| Shipping | Pending verification |
| Consultation fee | Pending verification |
| Dose-change price impact | Pending verification |
| Commitment required | Pending verification |
| Annual total (12-mo, all-in) | Pending verification |
| Cancellation terms | Pending verification |
| Refund policy | Pending verification |
| Pharmacy partner(s) | Pending verification |
| Pharmacy type (503A/503B/retail) | Pending verification |
| States served | Pending verification |
| Prescription pathway | Pending verification |
| Last price verified | Pending verification |
| Source URL | Pending verification |
Why the blanks? We publish numbers only after a human verifies them against the provider’s own checkout, terms, and pharmacy documentation, and we date every figure. Ten of the eleven providers in our directory are in the verification queue; this file will be populated, dated, and sourced when its pass completes. If you work for this provider or have a current receipt, corrections@onlineglp1providers.com accelerates the queue.
Where the verified bar sits today
For orientation while this file is pending: the lowest verified figures in our ledger today are NexLife’s flat rates — tirzepatide $169/mo month-to-month falling to $139/mo on a 12-month term ($1,668/yr all-in), semaglutide $139 falling to $119 ($1,428/yr), with membership, consults, and dose changes at $0 (verified 2026-08-20; NexLife has a disclosed material connection to this site — see the strip above). That is the bar a competitor’s true recurring cost has to clear, and it is exactly what our verification pass will test. Full field definitions live in the pricing ledger.
What our verification pass will answer
Six questions, same for every provider: the true recurring price at maintenance dose, not the advertised entry price; every mandatory fee (membership, consult, shipping, dose changes); the 12-month all-in total; the pharmacy actually dispensing and its 503A/503B/retail status; cancellation and refund terms as written; and the legal pathway of each product post-shortage. Answers get dates and source URLs, per our methodology.
The diligence script for Remedy Meds
Send the four-clause email before anything else: 503A pharmacy or 503B facility, named; per-lot or representative testing; the CoA for the lot you’d receive, lot-matched to your vial; and the maintenance-dose all-in total in writing. Then grade the response itself — speed, specificity, paperwork attached — because with thin-tier providers the answer’s quality is the review. Silence, urgency tactics, or “trust us” are answers too.
Where Remedy Meds fits
Fits exactly one shopper: the diligence-willing bargain hunter who treats the interrogation as mandatory and walks on any dodge. Wrong for anyone who won’t send the email — which, honestly, is most people, and they should shop the documented tiers instead.
Queue position and how it moves
Remedy Meds sits at position 8 of 10 in the public verification queue. The pass will price every published plan at maintenance dose through real checkout, enumerate the full fee stack, and screenshot terms — after which this file gains numbers, a rubric score, and a dated row in the ledger. Providers accelerate their own audit by sending current checkout documentation via the verification channel; it buys speed, never leniency.
Library files that matter here
For this model specifically: the eight questions that are this file’s whole method; how to grade whatever paperwork returns; the ad style that funds this tier; the adjacent territory to stay clearly out of.
FAQ
Are Remedy’s advertised prices real? Unverified claims until checkout audit — and in the thin tier, the pre-audit signal is how the company answers documentation requests, not how its ads read. Is Remedy safe to use? Platform and pharmacy are separate questions; safety lives at the dispensing pharmacy, which is why the named-pharmacy-plus-CoA demand comes before any price talk. Why do you even track providers this thin? Because shoppers meet them in ads and ask — and an honest pending file with an interrogation script beats the silence that lets ad spend stand in for answers.
Side-by-side files
Every head-to-head featuring Remedy Meds: vs Henry Meds · vs Hims · vs NexLife · vs Orderly Meds · vs Shed · vs Ro. Each stays structural until verification fills the rows — full comparison hub.
The bottom line
Cheap plus undocumented isn’t a price — it’s a question; send it in writing, and let the answer or its absence do the ranking.